Share Name Share Symbol Market Type Share ISIN Share Description
Summit Corporation LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 202.50p 195.00p 210.00p 202.50p 202.50p 202.50p 16,474.00 07:36:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.4 -20.1 -28.8 - 124.51

Summit Corp (SUMM) Latest News

More Summit Corp News
Summit Corp Takeover Rumours

Summit Corp (SUMM) Share Charts

1 Year Summit Corp Chart

1 Year Summit Corp Chart

1 Month Summit Corp Chart

1 Month Summit Corp Chart

Intraday Summit Corp Chart

Intraday Summit Corp Chart

Summit Corp (SUMM) Discussions and Chat

Summit Corp Forums and Chat

Date Time Title Posts
23/3/201721:14Summit - Climbing to new heights22,278.00
10/3/201615:43Professor Mark Wilcox Interview on C Diff1.00
23/5/201409:49Summit Corporation749.00
22/5/201416:46Summit Corporation plc37.00
21/5/201413:59Summit plc - Combating 'C. difficile' and lots more14,162.00

Add a New Thread

Summit Corp (SUMM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-03-24 16:40:13209.505,00010,475.00O
2017-03-24 16:26:06208.009311,936.48O
2017-03-24 16:01:49208.004491.52O
2017-03-24 15:50:39200.00350700.00O
2017-03-24 15:43:57208.004,90010,192.00O
View all Summit Corp trades in real-time

Summit Corp (SUMM) Top Chat Posts

Summit Corp Daily Update: Summit Corporation is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SUMM. The last closing price for Summit Corp was 202.50p.
Summit Corporation has a 4 week average price of - and a 12 week average price of -.
The 1 year high share price is - while the 1 year low share price is currently -.
There are currently 61,484,452 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Summit Corporation is £124,506,015.30.
football: Rns Summit Therapeutics plc Summit Therapeutics To Present At The Oppenheimer 27th Annual Healthcare Conference Oxford, UK, 15 March 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the Oppenheimer 27(th) Annual Healthcare Conference, 22 March 2017 at 2:10pm EDT in New York City. A live audio webcast of the presentation will be available through the Investors section on the Company's website, A replay of the webcast will be available soon after the live presentation
freemoney1: Hi H-M, Great work form you and Waterloo. As Waterloo points out any deal will give upfronts and milestones which will more than offset any further development and set-up costs. So to simplify calculation I just use the predicted peak sales and assume a 20% royalty. The Crystal Ball Calculator puts out values between £11-£16 per share ...depending which way the wind is blowing :-) So my point is with the share price below £2 it would seem a no brainer to invest at this level knowing the share is underpinned by that value in 3-4 years time and the 'free' gamble of the multi billion $ DMD programme hitting success... which could be worth £100's per share IMHO without further dilution. It's all looking very exciting... it'd be nice to see the FDX results and a deal soon to boost the share price to where it should be.... but then again if it stays low we can move more shares to ISA in April... win win :-) GLA
hugus maximus: I am no accountant but would expect a more modest $500 million per year C Diff market (that figure clearly dependent on whatever the drug's market price is) ... my stab at expectations over the next few months for C Diff:- As a consequence of a 3rd party major Pharma involvement with C Diff, might Summit realistically be looking for a downpayment of say $75 - 100 million and up to a 30% royalty? Therefore the initial C Diff drug effect on share price stabilising at around £3 ... until further income is eventually generated by sales which would then enhance the share price greatly? (The above having no bearing whatsoever on DMD share price enhancement which is obviously the big prize)
chrisatrdg: Per Free-Money from the other board this morning - any takers? 'Ridinilazole value per share ? This would seem to be a fundamental question for new investors now or LTH looking to top up at this price. We've recently been told the European and US agency are supportive of Summit Phase 3 programme and Ridnilazoles route to market. Knowing RDZ can be used as first and second line treatment and the market is worth about $1bln in annual sales we should be able to give the drug a share price value for 2021. If you can calculate that value and buy below that price then the gamble on the DMD programme is a free gamble as far as I see it. So what is the value of RDZ with Summit's roughly 62milion shares and assume it will be partnered giving Summit 20% royalties per year ? Lets assume for this exercise that since P3 is just a replica of the very successful P2 trial, only bigger, then we do not need to account for risk of success in my opinion. It’s just a matter of time to market now. I've worked out what I think but I'd be interested to see what others come up with and how you arrive at that value? Something to do while we wait and could be very interesting for those looking to invest.... in a 'free ride for shareholders' - Glyn AGM comment :-)'
freemoney1: Good share price reaction on both sides of the pond. But I see there is still a massive valuation difference between Sarepta and Summit. Market capitalisations : Summit : $110.53m Sarepta : $2,149.57m Once Ezutromid and Utrophin upregulation is proven (Q2/3) we should at least equal Sarepta in valuation but many would argue that since we can treat 100% of the population and we retain the most valuable market (US) we should exceed Sarepta's valuation. That's some upside!!!! We also have the second programme, C.Diff, which is due to deliver value to shareholders in the near term. Hopefully new investors with deep pockets are realising all this and our share price will continue to correct. GLA
hugus maximus: IMO Sarpeta share interest is a consequence of them finally rolling out eteplirsen after a slow start and the announcement to that effect (a couple of days ago) brings their FDA promise toward some sort of actual fruition. Hence Sarepta's slow drop in share price in the months after the FDA approval date, was due to expectations not being met quickly enough (both in demand and supply). There were many reports of difficulties until this weeks announcement that things had turned around. I wonder if their pipe line Exon 51 is too much a part of the distant future to produce todays share price effect ... although will perhaps have endorsed their position slightly? Maybe Summit are riding on Sarepta's coat tails and the market has turned from hot to cold to warm again about wariness of DMD market in general? Let's hope that the improved eteplirsen pipeline holds for a while, allowing Summit to come in with some serious guns blazing and their shares being bought on their own terms. IMO If Summit can prove with their empirical full comprehensive clinical testing that Ezutromid stands up to the plate (as opposed to the more subjective eteplisen research work which still casts elements of doubt), the DMD market will finally and categorically be banging at their door. EDIT - unless I've missed something majorly significant announced at the San Fran Health Conference which made Summit's shares move up independently last night?
hugus maximus: All IMHO ... Another view about valuations of similar companies and share price can be expressed in the valuation of SAREPTA, a DMD research company that was once in a very similar situation SUMMIT. When it's DMD drug showed promising results during P2 trials it's share price rocketed from under $1 in 2012 to over $50 in 2013 (a drug which only every had a potential cure rate of ~13% of DMD boys) The probable announcement from the FDA next week that Sarepta's failed DMD drug will be stripped of its permission to proceed, will see it's share price fall significantly and find the market looking for the next potential cure. The fact that Summit has so far been seen as a two bit small UK company in a chauvinistic american market place, has been the reason for the share slide. Aside from any value that Summit's C Diff drug has a result of its successful P2 trial results and potential deal with a large pharma, the potential DMD earnings will see the share price reach many multiples of where it is now over the coming months.
hugus maximus: Fascinating review of "things" buywell3! I'm going to save your note with the great hope that I can bring it back to haunt you one day. In addition to that, I will haunt you with my own predictions: 1. There will be a C Diff drug sale / licensing deal over the next 3-6 months. Glyn Edwards will most likely be presenting final reports next week in response to initial P2 data top line info. When as good as anticipated, that will make SMT19969 the "best drug in show" for treating C Diff by some large margin. Henceforth with a deal, we will have a financial injection anywhere between $60m-$150 million ... that alone should be responsible for doubling the share price before September. 2. The sadly less successful major DMD companies (Serepeta etc) all saw major share price upward movement during P2 trial ... their share price increased many multiples well before final P2 results. When we start to report results as the open trial progresses, that will add in major increments to an upward share price. The next 12 months will see a huge upward move in share price So there we are .. if you have invested here buywell, I'm sure you'll prefer my version of events! GLA HM
hugus maximus: SHOULD WE BE CONCERNED? Following Waterloo's remarks above: It's all well and good that we are funding a company that is all about "the science" but one wonders if Summit do deliver great results with the DMD tests, what will this actually do to the value of a company that has little profile and track record? Many of us have held a view that the science is all that's important, but given the company's success with C Diff P2 trials, (albeit waiting for final detailed data) and the tepid market reaction on the days following results were announced last year, one does wonder if Summit need to take a serious look at the lack of attention we still seem to have in the market place? I am not suggesting for a minute that we pay some ridiculous PR company a fortune to hype a profile .. but surely by now we should at least be getting name checks in the sort of Bloomberg article Waterloo points up above? I do worry that lack of profile will mean we're taken less seriously in the event of DMD success. The share price after SMT19699 has been proven to be at the very least "AN IMPROVEMENT ON CURENT STANDARD OF CARE IN THE TREATMENT OF C DIFF" is abysmal. Released into the Public Domain in 2015 are test results that state, together with an FDA Fast Track approval, we at least have a drug that is more effective than the best known current drug treatment for C Diff ... and Summit is still such a little known company with a share price that's on the floor. If DMD is a success, will Summit coming from nowhere help to enhance the companies value? Or does something have to be done to shine a wee light here? I am beginning to question this? Not long ago, a company's profile would have had little to do with it's eventual share price after a successful drug discovery. I am beginning to question whether this has changed? After being a significant share holder for 3 years, I can't say that I feel very comfortable about this side of "things". Is there more that Summit should be doing to change this ... or is this an irrelevance?
football: Summit Corporation – Follow Jim Mellon and buy at 115p - In August's edition of an obscure online publication, Jim Mellon tipped Summit PLC (SUMM) to do great things. Mr Mellon's track record and judgement in picking winners on AIM is second to none. Summit is a company Ben used to follow quite closely. The science it is developing is truly marvellous, even if its path has been a horribly bumpy ride lower for long term shareholders. No one is going to pretend that this has been a good stock hold over a long period of time, but that is in the past. Now priced at 115p (last seen) this could be a good opportunity to buy into a business, which has previously offered so much incredible potential. Ben last covered Summit, immediately after February's placement. He wasn't exactly complimentary about the price of this fundraising, but did point out that Summit was back on the watchlist. Admittedly we are very glad we didn't buy into it, as the share price has continued to fall, after recovering briefly. However, our reasons for considering this stock remain broadly the same. Since his appointment in the spring of 2012, CEO Glynn Edwards appears to have done a much better job in moving the company forward than his academic predecessors. Take a stroll through Summit's historical RNSs and compare the speed, content and tone of announcements before he joined the company with those since he took the helm and you should quickly see what I mean. Admittedly Summit's share price doesn't now reflect much of this development, but this could be what sets extremely savvy investors like Jim Mellon apart from the rest of the herd. Tom had a friendly exchange of emails with Jim today and that reinforces our view of what a good and clever man he is. On June 3rd this year, Summit announced a dreaded share consolidation, which was subsequently approved. The reputation of consolidations is not good among private investors and they are associated with share price pain. In the case of Summit, so far this feeling has been borne out, but now the company has only 41million shares in issue, this could be very positive if good news is around the corner. The tightly held nature of this stock could mean market makers struggle to satisfy demand if buyers are tempted back in their numbers. The consolidation itself was 20/1 so in old money Summit is worth 5.75p a share. This is a 12% discount to February's already discounted placement. Again it is easy to sympathise with stale holders who gripe about this, but the market has no memory. Reading between the lines and Mr Mellon's illusive reference to Summit has really caught my eye. He said "I am a fan of Summit plc, which is well financed and has two drugs in development". OK so this quote isn't much to go on, but when you consider Mr Mellon is a non-exec of Summit's and also holds 5.95% of the company through his trust Galloway Limited, perhaps he's just tipped us a little wink that he knows something pleasing is brewing in the background. You might think we are adding 2 + 2 and coming up with 117. We can take that on the chin, but even if we've misinterpreted Mr Mellon's comments, the rationale for buying into Summit now looks compelling. Http://
Summit Corp share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20170325 07:42:32